the aid library

LIST OPTIONS

Filter

14189

Sort by:

Direction:

Download (38)

View PDF (33)

Living with Chronic obstructive pulmonary disease (COPD)

Asthma and Lung UK (2022) CC2

Chronic obstructive pulmonary disease (COPD) is where air cannot get out of the lungs easily (the airflow is obstructed). COPD is a common condition that mainly affects middle-aged or older adults who smoke or have smoked. Jobs where people are exposed to dust fumes and chemicals also increase the r... more

Download (42)

View PDF (39)

Childhood respiratory disease linked to the enviroment

World Health Organization WHO (2009) CC2

Childhood Respiratory Diseases & the Environment learning objectives •To understand how the respiratory tract is affected by the environment •To describe respiratory diseases linked to the environment •To list one population-level intervention and one personal-level intervention for d... more

Download (24)

View PDF (32)

Identifying asthma in population studies: from single entity to a multi-component approach

Marks, G. B. (2005) CC2

Considerable energy has been expended over the last two decades in developing methods for identifying the presence of asthma among participants in population studies. The objective of this endeavour has commonly been to enable epidemiological research on risk factors for asthma, with the ultimate ai... more

Download (37)

View PDF (35)

Global, regional, and national prevalence of asthma in 2019: a systematic analysis and modelling study

Song, P.; Adeloye, D.; Salim, H.; et al. (2022) CC2

Asthma has a significant impact on people of all ages, particularly children. A lack of universally accepted case definition and confirmatory tests and a poor understanding of major risks interfere with a global response. We aimed to provide global estimates of asthma prevalence and cases in 2019 ac... more

Download (59)

View PDF (118)

2020 Brazilian Thoracic Association recommendations for the management of asthma

Menezes Pizzichini, M. M.; de Carvalho-Pinto, R. M.; Delfini Cançado, J. E.; et al. (2020) CC2

The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... more

Download (49)

View PDF (112)

Recomendações para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia – 2020

Menezes Pizzichini, M. M.; de Carvalho-Pinto, R. M.; Delfini Cançado, J. E.; et al. (2020) CC2

Download (39)

View PDF (90)

WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Download (44)

View PDF (107)

WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

Download (68)

View PDF (43)

Public health advice for gay, bisexual and other men who have sex with men on the recent outbreak of mpox

World Health Organisation (WHO) (2023) C_WHO

Outbreaks of mpox in newly affected countries have mostly been identified in communities of gay, bisexual and other men who have sex with men who have had recent sexual contact with a new partner or partners. Communities of trans and gender diverse people linked to the same sexual networks have also... more

Download (107)

View PDF (91)

Noncommunicable diseases and climate change

World Health Organisation (WHO) (2022) C_WHO

WHO has identified climate change as one of the greatest health threats of the 21st century and air pollution as the single largest environmental health risk. Noncommunicable diseases (NCDs), including cardiovascular diseases, diabetes, chronic respiratory disease and cancer, are the leading causes ... more

Download (74)

View PDF (91)

ACT-Accelerator Prioritized Strategy & Budget for 2021

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2021) CC

In 2021 ACT-Accelerator will intensify its drive for equity and scale in the delivery of essential COVID-19 tools, while managing emerging viral risks. To address these major shifts and maintain momentum, ACT-Accelerator has defined four strategic priorities for 2021: Rapidly scale up the delivery o... more

Download (161)

View PDF (215)

WHO global air quality guidelines: particulate matter (‎PM2.5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

World Health Organization WHO (2021) C_WHO

The global burden of disease associated with air pollution exposure exacts a massive toll on human health worldwide: exposure to air pollution is estimated to cause millions of deaths and lost years of healthy life annually. The burden of disease attributable to air pollution is now estimated to be ... more

Download (159)

View PDF (108)

Infection prevention and control and water, sanitation and hygiene measures in health-care settings and shelters/congregate settings in Gaza: Technical note, 22 February 2024

World Health Organization WHO (2024) C_WHO

The situation in the Gaza Strip is dire, with syndromic surveillance revealing high rates of infectious diseases. The risk of further spread may be exacerbated by several factors, including overcrowding, inadequate water and sanitation, disruption of routine healthcare services, and a dysfunctional ... more

Download (167)

View PDF (316)

Sanitary inspection packages – A supporting tool for the Guidelines for drinking water quality: Small water supplies

World Health Organization WHO (2024) C_WHO

A sanitary inspection is a simple, on-site evaluation (traditionally using a checklist) to help identify and support the management of priority risk factors that may lead to contamination of a drinking-water supply. Sanitary inspections are a well-established and widely-applied practice. They can su... more

Download (152)

View PDF (358)

Guidance: Integrating MHPSS and Peacekeeping: a Mapping and Recommendations for Practitioners - IASC Reference Group on Mental Health and Psychosocial Support in Emergency Settings (January 2024)

Inter-Agency Standing Committee (2024) C1

A major problem facing the world is how to build peace following the ravages of increasingly protracted armed conflict. Armed conflicts leave behind shattered, divided societies that are at risk of repeating cycles of violence, and therefore need concerted peacebuilding efforts. Conflicts also take ... more

Download (168)

View PDF (139)

La ingesta total de grasas en la prevención del aumento de peso malsano en adultos y niños: resumen de la directriz de la OMS

World Health Organisation (WHO) (2023) C_WHO

This guideline provides updated, evidence-informed guidance on the percentage of total fat in the diet to reduce the risk of unhealthy weight gain. This guideline is intended for a wide audience involved in the development, design and implementation of policies and programmes in nutrition and pub... more

Download (272)

View PDF (367)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (163)

View PDF (161)

Voluntary non-remunerated blood donations to ensure blood safety in the WHO South-East Asia Region to support universal health coverage

World Health Organisation (WHO) (2023) C_WHO

Access to safe blood and blood products is recognized as one of the key requirements for delivery of modern health care in the journey towards health for all. The foundation of safe and sustainable blood supplies depends on the collection of blood from voluntary non-remunerated and low-risk donors. ... more

Download (134)

View PDF (137)

A health promotion approach for reducing youth exposure to alcogenic environments: Snapshot series on alcohol policies and practice

World Health Organisation (WHO) (2023) C_WHO

The environment in which young people live, learn and play significantly affects their decisions about whether to consume alcohol. Environmental factors are the main risk factors driving alcohol consumption and related harm among young people. Environments that normalize alcohol consumption – term... more

Download (164)

View PDF (116)

Pandemic triad: HIV, COVID-19 and debt in developing countries

UNAIDS (2022) CC

This report analyses the intersection of HIV, COVID-19 and public debt in developing countries. The collision between COVID-19 and a crippling debt crisis have reversed decades of progress - putting present and future investments in health and HIV at risk. Pragmatic options to address the pandemic t... more